The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial
European Journal of Clinical Investigation · 2025-06 · 55 (6)
DOI: 10.1111/eci.14389 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 24.01.2025. Verfasst von Andrea Pasta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Crohn Disease, Diet, Mediterranean. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
The Crohn's disease exclusion diet (CDED) has been shown to induce remission in adult Crohn's disease (CD) patients. The aim of the study is to provide additional evidence‐based validation.
Methods
We conducted an open‐label, randomized trial on adult CD patients with mild‐to‐moderate symptoms to assess CDED efficacy in inducing symptomatic remission using Mediterranean diet as control. We evaluate demographic data, body mass index (BMI), Harvey‐Bradshaw Index (HBI), faecal calprotectin, and serum inflammatory indices at baseline, 12, and 24 weeks. Bioelectrical impedance analysis (BIA) was used to ensure the safety of the CDED group every 12 weeks.
Results
Twenty‐four patients were assigned to CDED, and 21 to controls, with no baseline differences among the parameters considered. Five CDED patients dropped out due to intolerance within the first 6 weeks. At 12 weeks, CDED patients showed significantly lower HBI and higher remission rates than controls. By 24 weeks, remission rates increased (70.8% vs. 38.1% at 12 weeks and 79.2% vs. 42.9% at 24 weeks; p = .027 and p < .0001, respectively), with significantly lower fibrinogen levels in the CDED group. The administration of CDED was associated with a significant decrease in BMI (25.8 kg/m 2 –24.5 kg/m 2 , p = .047), although BIA analysis showed a decrease in fat mass (18.2%–15.5%, p < .0001), while fat‐free mass and body cellular mass significantly increased at 12 weeks ( p = .001 and p = .042, respectively) and remained stable at 24 weeks.
Conclusions
The CDED was effective in inducing remission among patients with mild‐to‐moderate CD and appeared to be safe and well‐accepted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
- Dietetics and Clinical Nutrition Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
- Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
ORCID-Profile: Andrea Pasta, Elena Formisano, Edoardo Giovanni Giannini
Zitieren
APA
Pasta, A., Formisano, E., Calabrese, F., Apollonio, M., Demarzo, M. G., Marabotto, E., Furnari, M., Giannini, E. G., Pisciotta, L., & Bodini, G. (2025). The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial. European Journal of Clinical Investigation, 55(6). https://doi.org/10.1111/eci.14389
Vancouver
Pasta A, Formisano E, Calabrese F, Apollonio M, Demarzo MG, Marabotto E, et al. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial. European Journal of Clinical Investigation. 2025;55(6). doi:10.1111/eci.14389
BibTeX
@article{Pasta2025,
author = {Pasta, Andrea and Formisano, Elena and Calabrese, Francesco and Apollonio, Monica and Demarzo, Maria Giulia and Marabotto, Elisa and Furnari, Manuele and Giannini, Edoardo Giovanni and Pisciotta, Livia and Bodini, Giorgia},
title = {The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial},
journal = {European Journal of Clinical Investigation},
year = {2025},
volume = {55},
number = {6},
doi = {10.1111/eci.14389}
}
EUVIMED